$2,799.00
In Stock
Tremfeya is used to treat moderate to severe plaque psoriasis in adult patients eligible for systemic therapy.
A phase I study showed that guselkumab treatment resulted in decreased expression of IL-23/Th17 pathway genes and altered expression profiles of genes associated with psoriasis. This was demonstrated by comparing mRNA results from skin biopsies of psoriasis patients at week 12 with baseline data. In the same phase I study, guselkumab treatment resulted in improved histology at week 12, including decreased epidermal thickness and decreased T cell count. In addition, phase II and III studies showed a decrease in plasma concentrations of IL-17A, IL-17F and IL-22 in the guselkumab group compared to the placebo group. These results are consistent with the positive clinical effect observed with guselkumab in patients with plaque psoriasis.
Active ingredient: guselkumab
Prescription medicine
Storage temperature 2-8 degrees
